Skip to content

Study · Observational study · n = 53 · 1988

2 results

Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis.

Rizzato G, Tosi G, Schiraldi G, Montemurro L, Zanni D, Sisti S

Sarcoidosis1 Sept 1988Cited by 27 (Europe PMC)

PMID3227195 (opens in a new tab)PepBankPUB-03227195
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In steroid-treated sarcoidosis patients, salmon calcitonin was linked to less mineral loss: -2.15 versus -14.11% (P less than .001).

    In plain wordsIn steroid-treated sarcoidosis patients, salmon calcitonin was linked to less vertebral mineral loss than no calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseVertebral cancellous mineral loss
    Study

    n = 53

    Comparator
    Unprotected patients
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 I.U. daily for one month, then every two days · intramuscular · 15 monthsAs given in this study (human).

    Measurements

    Mineral loss
    −2.15%
    calcitonin
    Mineral loss
    −14.11%
    unprotected
    P value
    < 0.001
    calcitonin versus unprotected

    Source sentences

    Summary
    At the end of the study ML% averaged -2.15(+/- 2.27) in the sCT protected group, and -14.11(+/- 2.08) in the unprotected group (P less than .001).
    2 context sentences
    Summary · context
    We have studied 53 patients with chronic histologically-proven sarcoidosis, all needing steroids, in a follow-up of 15 months; 20 of them were protected with sCT (100 I.U. i.m. daily for one month, then every two days for all the time of the study), 33 were unprotected.
    Summary · context
    The two groups were matched for age, sex and total dose of prednisone.
  2. 02HumanObservational studyEfficacy outcome

    In sarcoidosis patients with initial Z score under -1, calcitonin was linked to less mineral loss: -2.80 versus -13.62% (P less than .01).

    In plain wordsIn sarcoidosis patients with low initial bone mineral, calcitonin was linked to less mineral loss than no calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseMineral loss with initial Z score under -1
    Study

    n = 37

    Comparator
    Unprotected patients
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 I.U. daily for one month, then every two days · intramuscular · 15 monthsAs given in this study (human).

    Measurements

    Mineral loss
    −2.8%
    calcitonin
    Mineral loss
    −13.62%
    unprotected
    P value
    < 0.01
    calcitonin versus unprotected, initial Z score under -1

    Source sentences

    Summary
    In these subgroups the ML% after 15 months averaged -13.62(+/- 2.9) in the unprotected group and -2.80(+/- 2.29) in the protected one (P less than .01).
    3 context sentences
    Summary · context
    We have also analysed the results limited to pts with initial Z score under -1 (19 sCT protected pts vs 18 unprotected).
    Summary · context
    We have studied 53 patients with chronic histologically-proven sarcoidosis, all needing steroids, in a follow-up of 15 months; 20 of them were protected with sCT (100 I.U. i.m. daily for one month, then every two days for all the time of the study), 33 were unprotected.
    Summary · context
    The two groups were matched for age, sex and total dose of prednisone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.